| 1 |
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) |
Eosinophilic Gastritis|Eosinophilic Gastroenteritis |
Biological: Benralizumab|Biological: Placebo |
AstraZeneca |
Phase 3 |
NCT05251909 |
2022-01-18 |
| 2 |
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) |
COVID-19|SARS-CoV-2 Acute Respiratory Disease |
Biological: COVID-19 Vaccine HIPRA|Biological: Cominarty (Pfizer-BioNtech) |
Hipra Scientific, S.L.U|Laboratorios Hipra, S.A.|National Institute of Hygiene and Epidemiology, Vietnam |
Phase 2 |
NCT05142514 |
2021-11-11 |
| 3 |
Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19) |
Covid19 |
Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|Biological: ChAdOx1-S not less than 2.5 횞 10^8 infectious units |
SK Bioscience Co., Ltd.|International Vaccine Institute|GlaxoSmithKline|Coalition for Epidemic Preparedness Innovations |
Phase 3 |
NCT05007951 |
2021-08-30 |
| 4 |
The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) |
COVID-19 Vaccines |
Biological: ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine|Other: Placebo (normal saline)|Biological: Astra Zeneca COVID-19 vaccine |
Vinbiocare Biotechnology Joint Stock Company|Arcturus Therapeutics, Inc. |
Phase 2|Phase 3 |
NCT05012943 |
2021-08-15 |
| 5 |
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis |
Non-cystic Fibrosis Bronchiectasis |
Biological: Benralizumab|Biological: Placebo to Benralizumab |
AstraZeneca |
Phase 3 |
NCT05006573 |
2021-07-21 |
| 6 |
Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19 |
SARS-CoV-2 Infection|COVID-19 |
Biological: Nanocovax|Biological: Placebo |
Nanogen Pharmaceutical Biotechnology Joint Stock Company |
Phase 3 |
NCT04922788 |
2021-06-07 |
| 7 |
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC |
COVID-19 Disease|SARS Pneumonia|Pneumonia, Viral|COVID-19 Vaccine |
Biological: COVIVAC|Biological: Phosphate-buffered saline |
Institute of Vaccines and Medical Biologicals, Vietnam|National Institute of Hygiene and Epidemiology, Vietnam|Hanoi Medical University|Center for Disease Control of Thai Binh Province |
Phase 1|Phase 2 |
NCT04830800 |
2021-03-10 |
| 8 |
A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult |
Covid19 Vaccine |
Biological: MVC-COV1901(S protein with adjuvant)|Biological: MVC-COV1901(Saline) |
Medigen Vaccine Biologics Corp. |
Phase 2 |
NCT04695652 |
2020-12-30 |
| 9 |
A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers |
COVID-19 |
Biological: Nanocovax|Biological: Placebo |
Nanogen Pharmaceutical Biotechnology Joint Stock Company |
Phase 1|Phase 2 |
NCT04683484 |
2020-12-10 |
| 10 |
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam |
Influenza |
Biological: IVACFLU-S |
Vietnam Military Medical University|Institute of Vaccines and Medical Biologicals, Vietnam|Vietstar Biomedical Research |
Phase 3 |
NCT04695717 |
2020-09-05 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.